Optimizing Lipophilic Active Softgels: Managing Oxidation, Stability, and Bioavailability Through Formulation and Packaging

Across finished dietary-supplement softgels containing omega-3 oils, phospholipids, fat-soluble vitamins, CoQ10/ubiquinol, astaxanthin, or comparable lipophilic actives, how do manufacturing exposure, shell composition, packaging, storage, and fill formulation affect oxidation, active-content loss, dissolution/release, physical stability, and oral solubilization/bioavailability?

Fill formulation (vehicle polarity, antioxidants, and emulsification state), packaging moisture-barrier properties, shell composition, and storage conditions each independently and materially affect oxidation, dissolution, active-content retention, and oral bioavailability in lipophilic-active softgels, with supply-chain temperature and oxygen exposure driving the majority of oxidation failures in commercial omega-3 products, hydrophilic fill vehicles and low-permeability packaging best preserving chemical and physical stability, gelatin shells outperforming starch in limiting digestion-induced lipid oxidation, and pre-emulsified or micellar fill formats substantially increasing absorption rate and peak plasma exposure relative to conventional non-emulsified oil-filled capsules.

Abstract

Across 24 sources encompassing market surveys, stability studies, in vitro digestion models, and human pharmacokinetic trials, the evidence consistently identifies fill formulation, packaging barrier properties, shell composition, and storage conditions as the dominant determinants of softgel quality for lipophilic actives. In commercial omega-3 softgels, 27–50% of products exceed at least one GOED voluntary oxidation limit (PV ≤ 5 meq/kg, p-AV ≤ 20, TOTOX ≤ 26) at the point of testing [1–4], with the preponderance of evidence indicating that this oxidation originates in the supply chain and retail distribution rather than at manufacture [3, 5]. Flavoring additives systematically confound p-AV and TOTOX measurements, rendering these metrics invalid for a large fraction of commercial products and artificially inflating apparent failure rates [1, 4, 4]. Fill vehicle polarity critically governs both dissolution stability and phase-separation risk during storage: hydrophilic vehicles (PEG 400) maintained curcumin phytosome dissolution through three months while oily vehicles caused substantial dissolution collapse [6], and soybean-oil fills limited water transfer to gelatin shells, preventing crosslinking and enabling complete altrenogest release across physiological pH [7, 7]. Gelatin crosslinking sufficient to cause rupture-test failure can develop within 18 months at 25 °C/65% RH [8, 8], and packaging permeability materially controls the rate of moisture-driven degradation: a high-barrier AquaBa® blister (WVTR 0.06–0.11 g/m²·day) extended silodosin content retention above 95% for over 12 months compared with more rapid degradation in standard PVC/PVDC [9, 9]. Shell material influences digestion-induced oxidation independently of pre-ingestion quality: bovine gelatin capsules generated approximately half the oxylipins of starch-shell capsules during simulated intestinal digestion without sacrificing ultimate lipolysis extent [10, 10]. Pre-emulsified delivery formats substantially improved oral bioavailability of lipophilic actives relative to conventional non-emulsified softgels—gelled-emulsion fish oil increased EPA Cmax 2.00-fold and AUC 1.45-fold [11], and nano-micellar astaxanthin achieved 1.87-fold higher Cmax with a markedly shorter Tmax, though without a significant AUC difference [12] —indicating that the solubilization rate-limiting step inherent to unmodified oil fills can be substantially overcome by formulation engineering. Collectively, the evidence points to a triangular failure landscape in which fill-shell water-activity management, packaging barrier selection, and excipient chemical compatibility must be addressed simultaneously, as superior packaging cannot eliminate fill-excipient interaction degradants [9] and formulation antioxidants alone do not reliably prevent supply-chain oxidation in commercial products [2].

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran these queries:

• "("softgel" OR "soft gelatin capsule" OR "vegetarian soft capsule") AND (lipid OR fish oil OR omega-3 OR phospholipid OR "fat soluble vitamin" OR coenzyme Q10 OR astaxanthin) AND (oxidation OR peroxide OR anisidine OR TOTOX OR rancidity OR aldehyde)"
• "("softgel" OR "soft gelatin capsule") AND (packaging OR blister OR bottle OR oxygen OR moisture OR permeability OR storage OR shelf-life OR nitrogen) AND (stability OR oxidation OR degradation)"
• "("softgel" OR "gelatin capsule") AND (crosslinking OR cross-linking OR pellicle OR dissolution OR disintegration OR precipitation OR crystallization OR self-emulsifying OR bioavailability)"

The searches returned 750 total results from Elicit.

We retrieved 681 papers most relevant to the query for screening.

Screening

Abstract screening

We screened in sources based on their abstracts that met these criteria:

• Primary experimental report: Is this a primary experimental, analytical, stability, dissolution, permeability, or bioavailability study rather than a review, protocol, editorial, patent, or conference abstract?
• Relevant dosage system: Does the title or abstract involve a softgel, soft gelatin capsule, plant-based soft capsule, or a capsule-shell/fill model explicitly intended to represent such a system?
• Lipid-based active or fill: Does the study address a lipid-based active/fill or an oxidation-reactive constituent relevant to omega-3 oils, phospholipids, fat-soluble vitamins, CoQ10/ubiquinol, astaxanthin, or comparable lipophilic supplements?
• Technical outcome: Does the report assess oxidation or chemical stability, packaging or permeability, shell cross-linking/dissolution, physical phase stability, solubilization, absorption, or bioavailability?
• Softgel Dosage Form: Does this study investigate finished softgels, softgel shell/fill models, or directly relevant softgel analogues containing lipophilic actives?
• Target Active Ingredients: Does this study examine softgels containing omega-3 oils, phospholipids, fat-soluble vitamins (A, D, E, K), CoQ10/ubiquinol, astaxanthin, or comparable lipophilic actives?
• Study Design: Is this study an experimental study, analytical study, stability study, dissolution study, permeability study, bioavailability study (human or animal), systematic review, or meta-analysis?
• Comparative Element: Does this study include at least one experimental comparator, control condition, or comparative analysis between different conditions/formulations?
• Quantitative Outcomes: Does this study report at least one quantitative or extractable outcome related to oxidation, active-content loss, dissolution/release, physical stability, or oral solubilization/bioavailability?
• Dosage Form Relevance: Does this study focus on softgels, softgel shell/fill analogues, or encapsulated lipid systems that provide mechanistic insights relevant to softgel performance (rather than focusing solely on tablets, capsules, emulsions, or other non-relevant dosage forms)?
• Formulation Focus: Does this study focus on dosage-form measurement evidence rather than being primarily focused on toxicological interpretation of oxidation products?

Papers that failed any criterion were automatically excluded; all other papers, including borderline ones, were screened in.

230 papers passed abstract screening and moved to full-text screening.

At abstract screening, the number of papers excluded for each primary reason was:

• Primary experimental report: n = 94
• Relevant dosage system: n = 283
• Lipid-based active or fill: n = 2
• Softgel Dosage Form: n = 39
• Target Active Ingredients: n = 8
• Comparative Element: n = 1
• Dosage Form Relevance: n = 23
• Formulation Focus: n = 1

Full-text screening

We then screened papers based on their full text using these additional criteria:

• Primary experimental report: Is this a primary experimental, analytical, stability, dissolution, permeability, or bioavailability study rather than a review, protocol, editorial, patent, or conference abstract?
• Relevant dosage system: Does the title or abstract involve a softgel, soft gelatin capsule, plant-based soft capsule, or a capsule-shell/fill model explicitly intended to represent such a system?
• Lipid-based active or fill: Does the study address a lipid-based active/fill or an oxidation-reactive constituent relevant to omega-3 oils, phospholipids, fat-soluble vitamins, CoQ10/ubiquinol, astaxanthin, or comparable lipophilic supplements?
• Technical outcome: Does the report assess oxidation or chemical stability, packaging or permeability, shell cross-linking/dissolution, physical phase stability, solubilization, absorption, or bioavailability?
• Quantitative or extractable outcome: Does the full text provide at least one usable quantitative or extractable outcome related to oxidation/chemical stability, active degradation, packaging/permeability, cross-linking/dissolution, physical phase stability, solubilization, or absorption?
• Relevant test system: Is the test system a finished softgel or a directly relevant softgel shell/fill/packaging model? If it is only a non-softgel encapsulated-lipid system, retain it only if it provides a mechanism directly relevant to softgel degradation and flag it as Tier 3 contextual evidence.
• Experimental condition or comparator: Does the report describe an experimental condition, storage/manufacturing variable, packaging comparator, formulation comparator, or other interpretable comparison relevant to the review question?

Papers were included in the final analysis only if they met every criterion; papers that failed or were borderline on any criterion were excluded.

24 papers passed full-text screening and moved to data extraction.

At full-text screening, the number of papers excluded for each primary reason was:

• Primary experimental report: n = 5
• Relevant dosage system: n = 17
• Lipid-based active or fill: n = 5
• Relevant test system: n = 3
• Full text not available: n = 176

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Full citation:

Give the complete citation: all reported authors, journal, publication year, and DOI or other persistent identifier. Do not invent missing bibliographic details.

Evidence tier and study design:

Classify as Tier 1 finished commercial/pilot softgel, Tier 2 softgel shell/fill/packaging model, or Tier 3 contextual non-softgel encapsulated-lipid system; state the experimental study design.

Lipid matrix and active:

Extract the lipid matrix/fill and active(s), including chemical form where reported.

Shell and encapsulation parameters:

Extract shell composition/type, capsule format, fill mass if reported, and all evaluated manufacturing variables: homogenization/shear, temperature, ribbon/drying exposure, headspace atmosphere, antioxidant/chelating system. State not reported when absent.

Packaging and storage parameters:

Extract container/blister material, barrier data including OTR/MVTR if reported, nitrogen/vacuum use, light, temperature, relative humidity, and storage duration.

Peroxide value:

Extract every relevant peroxide value with units, method, initial/final timepoint, and condition. Preserve exact numbers.

p-Anisidine value:

Extract every relevant p-anisidine value with units/method, initial/final timepoint, and condition. Preserve exact numbers.

TOTOX:

Extract reported TOTOX values with timepoints/conditions. If absent but matched paired PV and p-anisidine values are reported at the same timepoint/condition, calculate 2*PV+p-anisidine and explicitly label as calculated; otherwise state not calculable.

Secondary and tertiary oxidation products:

Extract quantitative aldehydes, MDA, 4-HNE, alkenals, volatile oxidation products, or other secondary/tertiary oxidation metrics, including method, units, condition, and timepoint.

Active chemical stability:

Extract initial and terminal assay/content, percent remaining or degraded, impurity profile, timepoint, and condition for lipophilic actives. Preserve exact values and units.

Dissolution and cross-linking outcomes:

Extract cross-linking/pellicle evidence and quantitative disintegration/dissolution/release outcomes, including USP apparatus, medium, enzyme addition, duration, temperature, and percent/time result.

Physical stability and emulsification:

Extract phase separation, precipitation/crystallization, droplet size/emulsification, and intestinal micellar solubilization outcomes with numbers and conditions.

Absorption and bioavailability:

Extract human or animal intestinal/lymphatic absorption or exposure outcomes and comparator, including numerical metrics and timing.

Failure mechanism and study limitation:

Classify the proposed mechanism as thermal, shear, oxygen/moisture ingress, oxidation-product-mediated cross-linking, packaging permeability, phase separation/precipitation, solubilization limitation, or other; quote the reported basis and key study limitation without inferring causality beyond the data.

Evidence Tier:

Classify the study according to the protocol tiering system:

• Tier 1: Finished commercial or pilot softgels
• Tier 2: Softgel shell/fill or packaging simulations
• Tier 3: Encapsulated-lipid systems mechanistically informative but not softgels Note the specific rationale for tier assignment.

Product Details:

Extract details about the softgel products studied, including:

• Lipophilic active ingredients (omega-3 oils, phospholipids, fat-soluble vitamins, CoQ10/ubiquinol, astaxanthin, or comparable actives)
• Active concentration/dose
• Shell composition (gelatin type, plasticizers, additives)
• Fill formulation (carrier oils, solubilizers, antioxidants)
• Commercial vs. experimental products
• Product identification when available

Studied Factors:

Extract all manufacturing, formulation, storage, and packaging factors that were varied or compared in the study, including:

• Manufacturing exposure conditions (temperature, oxygen, light, processing time)
• Shell composition variations
• Packaging materials and conditions (bottle type, headspace, barrier properties)
• Storage conditions (temperature, humidity, light, duration)
• Fill formulation variables (antioxidants, carriers, ratios)
• Any other factors hypothesized to affect softgel quality

Measured Outcomes:

Extract all measured outcomes relevant to softgel quality and performance, including:

• Oxidation markers (peroxide value, p-anisidine, TOTOX, aldehydes, off-flavors)
• Active content loss (% degradation, potency retention)
• Dissolution/release characteristics (disintegration time, release rates, pH conditions)
• Physical stability (shell integrity, leakage, appearance changes)
• Bioavailability/solubilization (Cmax, AUC, Tmax, absorption parameters)
• Measurement methods and conditions for each outcome

Effects Found:

Extract the specific effects of studied factors on measured outcomes, including:

• Direction of effect (increase/decrease/no change)
• Magnitude of effect (numerical values, fold-changes, percentages)
• Statistical significance and confidence intervals when reported
• Dose-response or time-course relationships
• Comparative rankings when multiple conditions tested
• Notable threshold effects or optimal conditions identified

Study Design:

Extract methodological details affecting evidence quality, including:

• Study type (experimental, analytical, stability, dissolution, permeability, bioavailability)
• Comparator conditions or controls used
• Sample size and replication
• Time points studied
• Analytical methods and validation
• Blinding and randomization (for bioavailability studies)
• Limitations acknowledged by authors

Results

Characteristics of Included Studies

All 24 sources provided full text for extraction. The corpus spans considerable heterogeneity in study type, active ingredients, and design. Sixteen sources were classified as Tier 1 (finished commercial or pilot softgels) [1–5, 7–9, 11, 12, 14, 16–20, 22], three as Tier 2 (softgel shell/fill or packaging simulations) [6, 13, 21, 24], and two as Tier 3 (encapsulated-lipid systems mechanistically informative but not softgels) [15, 23]. The Tier 1 market-survey studies (Hands et al., Yenipazar & Şahin-Yeşilçubuk, Halvorsen & Blomhoff, Jackowski et al., Jairoun et al., Heller et al.) collectively tested more than 300 distinct commercial omega-3 supplement products [1–5, 14]. Human pharmacokinetic data are contributed by two randomized crossover studies (Haug et al.; Khayyal et al.) and one small before–after supplementation study (Saito et al.) [11, 12, 22]. In vivo bioequivalence evidence from a 28-gilt crossover trial is contributed by Xu et al. [7]. The remaining studies generate in vitro dissolution, oxidation, physical stability, shell rheology, moisture-sorption, or digestion-model data.

Effects

Oxidative Status of Finished Omega-3 Softgels

Summary of oxidation measurements across market surveys

Across the six market surveys, the proportion of products exceeding at least one GOED voluntary oxidation limit ranges from roughly 27% to 50% [1–4]. The GOED voluntary limits of PV ≤ 5 meq/kg, p-AV ≤ 20, and TOTOX ≤ 26 serve as the reference threshold in all studies that apply them [1–4, 14]. Halvorsen & Blomhoff measured only PV and alkenals rather than p-AV/TOTOX, reporting omega-3 supplement PVs of 1.04–10.83 meq/kg against fresh vegetable oils of 0.60–5.33 meq/kg, alongside alkenal concentrations of 158.23–932.19 nmol/mL versus 33.24–119.04 nmol/mL for fresh vegetable oils [5, 5]. This finding that omega-3 supplements already contain considerably more secondary oxidation products than fresh vegetable oils at the point of sale is consistent with the supply-chain origin of oxidation highlighted by Heller et al., who found that only 8% of tested products had PV/pAV ratios greater than one, indicating minimal laboratory-stage oxidation and predominantly pre-purchase deterioration [3].

Effect of flavoring on apparent oxidation

The most consistent and quantitatively large driver of measured oxidation values across studies is the presence of added flavorings. Hands et al. found that flavored products had a mean TOTOX of 59.1 versus 20.2 for unflavored products, a statistically significant adjusted difference of 20.7 TOTOX units (95% CI 9.3–32.0; P = 0.01) [4], with 94% of flavored products failing the p-AV ≤ 20 criterion compared with 0% of unflavored products [4]. Jackowski et al. similarly found that flavored softgels and children's products had significantly higher anisidine values and TOTOX than unflavored softgels [1], and children's products—nearly 80% of which contained flavor additives—had significantly higher primary, secondary, and TOTOX than all other product categories [1]. Heller et al. reported exploratory p-AV values for flavored products of up to 217 (for a citrus-flavored children's product) and confirmed that the p-AV assay is invalid for flavored oils because aldehydes in natural or synthetic flavorings and pigments interfere with the colorimetric measurement, with lemon flavoring reported to increase apparent p-AV more than 12-fold [3, 4]. Yenipazar & Şahin-Yeşilçubuk similarly found that lemon-flavored syrup S3 produced unreliable p-AV results, preventing calculation of TOTOX for that product [14]. These observations collectively indicate that the elevated oxidation signal observed in many flavored supplements reflects assay interference rather than genuine lipid oxidation, a critical confound for interpreting market-survey TOTOX data.

Effect of dosage form, packaging, and storage duration on oxidation

When restricting comparison to unflavored products, dosage form emerges as a meaningful predictor. Yenipazar & Şahin-Yeşilçubuk found that encapsulated omega-3 products (maximum end-of-storage PV 7.62 meq/kg, TOTOX 30.44) were substantially more stable than syrups (maximum PV 44.60 meq/kg, TOTOX 96.94), with the protective effect of the capsule shell and individual packaging attributable to reduced oxygen contact [14, 14]. Jairoun et al. found that chewable products had the lowest mean PV (0.70 meq/kg) and TOTOX (1.40) among dosage forms, while capsules had the highest PV (9.11) and TOTOX (30.10), suggesting that fill volume and headspace exposure at opening may contribute [2, 2]. Jackowski et al. found that unflavored encapsulated products had significantly lower secondary and TOTOX oxidation than bulk oils and flavored products [1].

Individual packaging format showed a striking protective effect in the Yenipazar & Şahin-Yeşilçubuk study: individually packaged chewable G3 (individual blister) ended storage with PV of only 0.73–0.93 meq/kg and TOTOX of 3.69–3.87, compared with G1 (individual plastic/aluminum) at PV 24.82–26.14 and TOTOX 58.78–65.76 after 29 days at room temperature [14, 14]. Products from the same company but sourced from different stores showed significant differences, indicating batch or supply-chain variability [14].

Jairoun et al. found that aluminum-strip packaging was associated with higher PV (mean 11.57 meq/kg) compared with amber-colored (5.44) or transparent packaging (4.76; P = 0.042) [2], while amber packaging was associated with higher P-AV (12.67 vs. 11.48 for transparent and 8.40 for aluminum strips; P = 0.052) [2]. These associations are cross-sectional and potentially confounded by product type; the authors acknowledged that packaging colour and product characteristics were not independently controlled [2].

Halvorsen & Blomhoff reported a significant negative correlation between PV and days until expiry across omega-3 supplements (r = −0.557; P < 0.001), consistent with progressive in-package oxidation, though no such trend was observed for alkenal concentration [5]. Jackowski et al. found that approximately 18% of products with 1–3 years remaining to expiration were already approaching at least one voluntary oxidation limit, raising concern about in-package stability over the product shelf life [1].

Omega-3 concentration and vitamin E as fill formulation variables

Jairoun et al. found strong positive correlations between total omega-3 fatty-acid concentration and all three oxidation markers: r = 0.816 for PV, r = 0.492 for P-AV, and r = 0.813 for TOTOX [2], suggesting that higher PUFA density increases oxidative burden. Presence of vitamin E in the fill (15/44 products) was not associated with significantly lower oxidation markers [2], a finding consistent with Saito et al., who administered EPA capsules containing 4 mg RRR-α-tocopherol equivalent daily and found no significant change in plasma TBARS or plasma, RBC, or platelet α-tocopherol levels after one week of supplementation—concluding that the capsule vitamin E content appeared sufficient for short-term antioxidant protection [22, 22]. Neither the UAE nor Canadian market-survey data permitted mechanistic conclusions about antioxidant efficacy, as product composition details and manufacturing histories were not available.

Dissolution, Release, and Shell Integrity

Disintegration and dissolution of finished softgels

The most striking evidence for dissolution failure comes from Bachour et al., who demonstrated that 18 months of storage at 25 °C/65% RH converted capsules that passed the USP <2040> rupture test within 4:40–8:50 minutes into capsules that failed after 52:33–60:00 minutes across all six replicates [8]. The failed capsules formed a thin, rubbery, water-insoluble clear cross-linked protein membrane that prevented fill release [8]. Addition of proteolytic enzymes (pepsin, pancreatin, papain, bromelain) to the test medium reduced rupture times to 28–49 minutes across the four media tested, but all stability-exposed capsules still failed the rupture criterion [8]. The authors cautioned that in vitro tests may over-discriminate relative to in vivo performance, as mechanical forces from stomach contents might rupture even cross-linked capsules in vivo [8].

By contrast, Xu et al. demonstrated that gelatin softgels manufactured with a soybean-oil fill and BHA/BHT antioxidants achieved rapid and complete ALT release (>90% by 45 minutes) across pH 1.2, 4.3, and 6.8 with 1% SDS, maintained shell integrity at 40 °C, and showed no cross-linking or pellicle formation under these conditions [7]. Shell adhesion and leakage were observed only at 60 °C [7]. The difference between these outcomes is likely attributable to the fill composition: Xu et al. employed a soybean-oil fill specifically to reduce water transfer from the gelatin shell and thereby limit cross-linking [7], whereas the Bachour et al. product contained an uncharacterized hydrophilic oil-based fill exposed to 65% RH for 18 months [8].

The Maciejewski et al. Tier 2 study provides mechanistic context for the gastro-resistant variant: gelatin-CAP-carrageenan films released less than 10% diclofenac during 120 minutes in 0.1 M HCl across all stirring rates, with release at pH 6.8 occurring only at 150 rpm through breach formation rather than uniform shell dissolution [13, 13]. Sealing imperfections were the principal reproducibility problem, causing some capsules to fail acid resistance at the seal before the intended buffer-stage release [13].

Allam et al.'s Tier 2 data illustrate how fill vehicle type affects dissolution independently of shell integrity: curcumin dissolution at 60 minutes ranged from 13% (pure Miglyol 812 fill) to 85% (40% KLS P124 surfactant) and was substantially driven by curcumin solubility in the vehicle—reported as 3.56 mg/g in Miglyol, 41 mg/g in Cremophor EL, and approximately 115 mg/g in PEG 400 [6, 6]. After three months of storage at 25 °C/65% RH, oily-vehicle formulations F9 and F10 showed sharply decreased dissolution, attributed to curcumin salting out from the phytosome complex, whereas PEG 400-based F13 was unchanged [6, 6].

Physical Stability, Shell Parameters, and Packaging

Shell rheology and gelatin grade

Molokhova et al. compared five gelatin grades from different geographic suppliers (China, Poland, Italy, Germany, France) with jelly strengths of 11.60–16.80 N and found that the optimal gelatin-mass rheological range for successful rotary-matrix encapsulation was characterized by viscosity of 11.46–5028.76 Pa·s and shear stress of 2788–2808 Pa at 60 °C [20]. Gelatin masses from Italian and German sources (grades 3 and 4, jelly strength 14.25 and 15.50 N) produced capsules with strong seams and clean cutting, whereas the French source (grade 5, highest jelly strength 16.80 N) required elevated sealing temperature, produced occasional unglued seams, and yielded rigid, brittle capsules [20]. Over three years of storage, essential-oil content (Lipovitol and Limoneol) decreased by only 4.88% and 5%, respectively, remaining within the ±10% permissible deviation [20], establishing that gelatin shells—when made from grades within the rheological optimum—can retain volatile lipophilic actives over long storage durations.

Owczarek & Łukowska-Chojnacka found that gelatin-mass viscosity at 65 °C initially measured 10,600–11,200 mPa·s (within the 7,000–15,000 mPa·s acceptance range) but increased substantially during storage at 40 °C/75% RH, exceeding the acceptance range through day 7 (17,284–30,937 mPa·s), returning to acceptable range on days 14–30, and falling below the range by day 40 (5,543 mPa·s) [17]. This time-dependent viscosity evolution at elevated temperature and humidity has implications for manufacturing scheduling and intermediate-storage conditions.

Moisture sensitivity and thermal stability

Li et al. quantified the moisture-sorption behavior of seamless gelatin popping capsules, finding that hardness decreased from approximately 1,500 g at 25 °C to approximately 900 g at 32 °C and 500 g at 45 °C, with commercial viability lost at ≥37 °C due to structural and textural changes [19, 19]. Moisture adsorption at 68% RH saturated within two hours and followed first-order kinetics (R² = 0.9700–0.9712 across temperatures) [19]. Recommended storage conditions were 43–61% RH and below 37 °C [19]. ATR-FTIR identified moisture-binding sites at O–H stretching (3273 cm⁻¹), amide-I C=O (1630 cm⁻¹), and amide-II N–H (1544 cm⁻¹), and SEM revealed surface cracking and local agglomeration at higher storage temperatures [19].

Packaging barrier properties and chemical stability

Visa et al. provide the most quantitatively detailed packaging comparison, testing PVC/PVDC blisters (WVTR 0.65 g/m²·day) against AquaBa® DX 200 (WVTR 0.06–0.11 g/m²·day; OTR 0.07–0.13 cm³/m²/day/bar) for silodosin soft capsules [9]. AquaBa® packaging preserved SLD content above 95% for over 12 months at 25 °C/60% RH and 30 °C/65% RH, whereas PVC/PVDC showed significantly greater SLD degradation at 40 °C/75% RH after 3 months (P < 0.05) [9, 9]. Critically, impurity 1—formed through a drug–Capryol® 90 interaction—exceeded its 0.3% ICH Q3B(R2) specification limit at six months under all tested conditions regardless of packaging [9], indicating that while superior barrier packaging can delay moisture-driven hydrolysis, it cannot eliminate excipient-mediated degradation. First-order kinetic modeling showed a markedly higher activation energy for dehydrosilodosin formation in AquaBa® (51.5 kcal/mol) than in PVC/PVDC (15.8 kcal/mol), confirming that moisture ingress is the primary driver of hydrolytic degradation in the less-protective packaging [9].

Kchaou et al. (Tier 2) corroborated this packaging-permeability mechanism using gelatin-film pouches filled with flaxseed oil: after 21 days at 50 °C, pouches maintained PV of 0.48–0.87 mMoles cumene hydroperoxide equivalent/g oil versus 6.75 and 9.40 for closed-bottle and open-bottle controls [24]. Oxygen permeability of the four pouch formulations was very low (0.30–0.50 cm³/m²·day), and neither heat treatment at 120 °C nor glucose-induced Maillard crosslinking significantly altered oxygen permeability [24, 24]. TBARs in pouch-stored oil decreased from day 4 to day 21, consistent with decomposition of primary oxidation products rather than continuing secondary-oxidation accumulation, while control oils showed steadily rising TBARs throughout [24].

Owczarek & Łukowska-Chojnacka also found that the shell dye concentration affected physical packaging compatibility: capsules containing 0.4% or 0.5% ammonia-sulphite caramel (E150d) stuck to the blister during storage, whereas undyed placebo capsules did not [17]. API (vitamin D3) concentration was unaffected by dye level over six months at 25 °C/65% RH [17], indicating that the sticking problem is a physical rather than chemical compatibility issue.

Fill Formulation Effects on Oxidative and Chemical Stability

Antioxidant systems in fills

Owczarek & Łukowska-Chojnacka compared four antioxidant conditions in vitamin D3 softgel fills (no antioxidant, α-tocopherol alone, BHT alone, and their combination) and found that all formulations met the 95–105% API assay criterion after one month at 40 °C/75% RH, with vitamin D3 content ranging from 98.2% to 100.0% regardless of antioxidant treatment [17, 17]. Although no antioxidant-related degradation was observed at this timepoint, the choice of carrier oil had more impact on long-term stability: at 40 °C and six months, one MCT-oil batch fell to 94.0% and one safflower-oil batch fell to 96.4%, with safflower oil described as having a shorter post-opening shelf life and requiring nitrogen protection due to oxidation susceptibility, while MCT oil did not require nitrogen protection and yielded more reproducible chromatographic backgrounds [17, 17].

Hwang et al. (Tier 3) studied wax concentrations as an oxidation-modulation variable in fish-oil oleogels and found that a prooxidant threshold exists at higher concentrations: 9% sunflower wax oleogels oxidized faster than 1–7% oleogels at 35 °C, and heating at 90 °C—which eliminated the gelling effect—revealed net prooxidant activity of wax based on EPA/DHA loss and olefinic-proton loss [15]. At storage temperatures of 35 °C, all 3% wax oleogels showed slower oxidation than bulk fish oil, with candelilla wax providing the broadest protection across both PV and conjugated diene metrics [15]. Cooling rate was another controllable manufacturing variable: increasing cooling rate from 5.3 to 25.3 °C/min reduced PV and CDV, consistent with formation of a denser wax crystal network that restricts oxygen diffusion [15].

Xu et al. demonstrated that fill solvent selection is a primary formulation lever: ALT solubility in ethyl acetate was 96.97 ± 0.88 mg/mL versus negligible aqueous solubility [7], and the antioxidants BHA and BHT were included to prevent oxidative degradation of the lipophilic fill [7]. ALT content was stable (>99%) under six-month accelerated storage at 40 °C/75% RH [7], demonstrating that a well-designed fill formulation combining appropriate carrier oil, co-solvent, and antioxidants can achieve excellent active-content retention in a finished gelatin softgel.

Allam et al. showed that vehicle polarity fundamentally governs dissolution stability over time: after three months of storage, oily fills (F9 with KLS P124/Miglyol 812; F10 with KLS P124/Miglyol 812 semisolid) showed sharply decreased curcumin dissolution, whereas the PEG 400-based hydrophilic fill (F13) showed no change [6]. TEM revealed curcumin salting out from the phytosome complex in oily vehicles, identified as the mechanism of dissolution loss [6].

Effect of encapsulation material on digestion-induced oxidation

Alberdi-Cedeño et al. provide the only direct comparison of two commercial shell materials (modified corn starch vs. bovine gelatin) on oxidation during gastrointestinal digestion. Using 500 mg black seed oil capsules, they found that total free oxylipins after gastric digestion were 124 ± 13.9 MRM peak-area units for starch-encapsulated oil (G-BS1) versus 37.7 ± 9.69 for gelatin-encapsulated oil (G-BS2)—approximately a 4-fold difference (P < 0.05) [10, 10]. After intestinal digestion, starch capsules generated approximately 2-fold more oxylipins (196 ± 33.2 vs. 97.0 ± 7.04; P < 0.05) [10]. The authors proposed that starch produced smaller, more numerous oil droplets during oral and gastric digestion (greater particle concentration, confirmed by nanoparticle tracking analysis), increasing lipid-lipase contact area and thereby accelerating both lipolysis and oxidation [10]. Lipid bioaccessibility at intestinal completion was not significantly different between shells (63.3 ± 7.05% vs. 60.2 ± 3.70%) [10], meaning that the reduced digestion-induced oxidation of gelatin capsules was achieved without sacrificing ultimate hydrolysis extent.

Otálora et al. (Tier 2) reported very low bioaccessibility for the predominant PUFAs in gelatin/cactus-mucilage soft capsules filled with sacha inchi oil: α-linolenic acid 1.70%, linoleic acid 1.46%, and oleic acid 35.8% [21]. The authors attributed this primarily to rapid gastric proteolysis of gelatin reducing matrix barrier protection and the low cactus-mucilage proportion limiting enzymatic resistance [21]. Oxidative by-products including 10,13-octadecadienoic acid methyl ester and propanal were identified after digestion [21].

Haug et al. provide the most direct Tier 1 evidence for how delivery vehicle emulsification state influences bioavailability: a gelled-emulsion format delivering pre-emulsified TAG fish oil increased EPA AUC₀–₂₆ₕ by 45% (ratio 1.45; 95% CI 1.13–1.86; P = 0.003), EPA+DHA AUC₀–₂₆ₕ by 43% (ratio 1.43; 95% CI 1.05–1.96; P = 0.024), EPA Cmax 2.00-fold (P = 0.003), and DHA Cmax 2.16-fold (P = 0.017), compared with conventional TAG fish-oil softgels [11]. In vitro, the gel matrix dissolved within 20 minutes in artificial gastric juice at pH 1.2/37 °C, releasing stable oil droplets with a mean volume diameter of 1.81 ± 0.02 µm, whereas oil from softgels was not emulsified and merged on top of the aqueous phase [11]. DHA AUC was not significantly different (P = 0.177), and the Tmax for EPA was 2 hours for the gelled emulsion versus 6 hours for the softgel [11].

Oral Bioavailability and Solubilization

These three studies address solubilization by different mechanisms. For omega-3 fatty acids, Haug et al. demonstrate that the emulsification state of the fill at the point of gastric contact is the critical determinant of short-term absorption rate and Cmax [11]; the gelled-emulsion format is not a conventional softgel but rather a competing delivery system that illustrates the solubilization limitation inherent to non-emulsified oil in a standard softgel [11]. For astaxanthin—a carotenoid with very low aqueous solubility—Khayyal et al. show that nano-micellar formulation (NovaSOL®) nearly doubled Cmax (7.21 vs. 3.86 µg/mL) and halved Tmax (3.67 vs. 8.50 hours) relative to a native astaxanthin-glycerol preparation, without a significant difference in AUC₀₋∞ [12]. The absence of a significant AUC difference despite markedly different Cmax and Tmax values suggests that the micellar format primarily accelerates absorption rather than increasing total bioavailability [12]. For the steroid altrenogest in gilts, the lipophilic softgel fill achieved bioequivalence to the commercial oral solution at equivalent doses, with no significant differences in Cmax, Tmax, or AUC [7], demonstrating that a well-formulated softgel can match solution bioavailability for highly lipophilic actives.

Thematic Analysis

Theme 1: Flavoring as a Dominant Confounder of Market-Survey Oxidation Data

The addition of flavorings to omega-3 softgels introduces a systematic positive bias in p-AV determinations that renders TOTOX values uninterpretable for flavored products. Hands et al. found that 94% of flavored products failed the p-AV ≤ 20 criterion compared with 0% of unflavored products, yet this difference is substantially attributable to aldehyde interference rather than genuine lipid secondary oxidation [4, 4]. GOED explicitly excludes flavored oils from p-AV testing for this reason [4]. Heller et al. reported individual flavored-product p-AV values reaching 217 for a citrus-flavored children's supplement [3], and Jackowski et al. found that visual AOCS titration endpoint interference prevented peroxide testing in 31 of 171 products [1]. Yenipazar & Şahin-Yeşilçubuk entirely excluded one product (lemon-flavored syrup S3) from p-AV and TOTOX analysis [14]. This confound has important regulatory implications: a large fraction of commercial omega-3 supplements—particularly children's and specialty products—cannot be validly assessed for secondary oxidation using the standard p-AV assay, and market-survey failure rates based on TOTOX should therefore be interpreted conservatively when flavored products are included.

Theme 2: Supply Chain and Post-Manufacture Oxidation as the Primary Failure Mode

Multiple lines of evidence across studies suggest that oxidation in commercial omega-3 softgels develops predominantly between manufacture and point of sale, rather than during consumer use or laboratory processing. Heller et al. found that only 8% of tested products had PV/pAV ratios greater than one, indicating minimal further oxidation during sample processing and that the measured oxidation was largely pre-purchase [3]. Halvorsen & Blomhoff found a significant negative correlation between remaining shelf life and PV across omega-3 supplements (r = −0.557; P < 0.001) [5], suggesting that products deteriorate progressively in distribution. Jackowski et al. found that approximately 18% of products with more than one year remaining to expiration were already approaching at least one voluntary oxidation limit [1]. Heller et al. noted that products may have met oxidation limits at manufacture and that finished encapsulated products lack standardized storage recommendations comparable to those for pharmaceutical products [3]. Together, these findings point to inadequate temperature, light, and oxygen controls during retail storage and transit as a critical quality-failure mechanism, independent of the inherent formulation of the product.

Theme 3: Shell Material and Digestion-Induced Oxidation as Opposed Quality Dimensions

Alberdi-Cedeño et al. provide the clearest demonstration that shell material choice creates a tradeoff between the rate of gastric lipolysis (potentially desirable for rapid nutrient availability) and digestion-induced lipid oxidation (potentially harmful). Starch capsules produced 4-fold more total oxylipins than gelatin capsules during gastric digestion, attributed to more and smaller oil droplets providing greater lipase-accessible surface area [10, 10]. However, neither shell material significantly affected the ultimate extent of intestinal lipolysis (63.3% vs. 60.2%) [10]. The authors recommend gelatin as the preferred encapsulant for oxidation-sensitive oils [10]. This finding has direct relevance to the broader review question because it establishes that the shell composition affects not only pre-ingestion oxidative stability but also the trajectory of lipid oxidation during GI transit—an endpoint not captured by conventional product quality-control assays measuring PV, p-AV, and TOTOX in the finished product.

Theme 4: The Emulsification State of the Fill Determines the Solubilization Rate-Limiting Step

Both human PK studies (Haug et al.; Khayyal et al.) and the in vitro digestion data from Haug et al. converge on the conclusion that the solubilization limitation for lipophilic actives in conventional softgels arises from the non-emulsified state of the oil fill at the point of gastric contact. Conventional softgels release oil as a coalescing phase that is not pre-emulsified [11], requiring gastric and intestinal peristaltic forces and bile-salt micellization to generate absorption-competent particle sizes. Pre-emulsification (gelled emulsion format; Haug et al.) or nano-micellar formulation (NovaSOL®; Khayyal et al.) bypasses this rate-limiting step, increasing Cmax 2.00-fold for EPA [11] and 1.87-fold for astaxanthin [12] relative to conventional oil or native-active comparators. That AUC₀₋∞ was not significantly different in the astaxanthin study [12] suggests the conventional softgel can eventually achieve similar total absorption but does so more slowly and with lower peak concentrations—a relevant distinction for actives where rapid saturation of target tissues matters.

Theme 5: Packaging Permeability as a Modifiable Determinant of Chemical Stability

The Visa et al. pharmaceutical stability study provides the most quantitatively rigorous evidence that packaging permeability directly controls the rate of moisture-driven active degradation in softgels. The approximately 6-to-10-fold lower WVTR of AquaBa® versus PVC/PVDC blister materials translated into measurably lower dehydrosilodosin formation and superior SLD content retention across all tested temperatures [9, 9]. The activation energy difference for dehydrosilodosin formation (51.5 vs. 15.8 kcal/mol in AquaBa® vs. PVC/PVDC) mechanistically confirms that reduced moisture ingress substantially decelerates hydrolytic degradation [9]. Kchaou et al. (Tier 2) demonstrate the equivalent principle for lipid oxidation: gelatin film pouches with OTRs of 0.30–0.50 cm³/m²·day preserved flaxseed oil against oxidation at 50 °C for 21 days, with PVs 8–19-fold lower than open-bottle controls [24, 24]. Li et al. show that the capsule shell itself functions as a moisture barrier whose protection capacity is temperature-dependent: at ≥37 °C, structural changes cause moisture uptake to increase rapidly, potentially increasing oxygen permeability and active-degradation rates [19]. Collectively, these findings indicate that packaging barrier selection and storage temperature control are interdependent tools for active retention in softgels containing moisture-sensitive or oxidation-labile lipophilic actives.

Synthesis

Reconciling Heterogeneous Findings on Oxidation Compliance Rates

The Apparent Inconsistency in Reported GOED TOTOX Compliance Rates

The apparent inconsistency in reported GOED TOTOX compliance rates—ranging from 73% in the UAE study (Jairoun et al.) to 50% failure in the Canadian study (Jackowski et al.)—is substantially explained by three factors operating simultaneously. First, the Canadian study included flavored softgels and children's products in the TOTOX calculation, both of which are known to produce inflated anisidine values from flavor interference [1, 4]; restricting to unflavored products reduces the failure rate considerably. Second, the UAE and Australian studies analyzed products on the day of collection without knowledge of supply-chain temperature history [2, 3], whereas the Canadian and US studies include products with longer remaining shelf lives and therefore more opportunities for in-distribution oxidation. Third, oil-source heterogeneity contributes: Jackowski et al. found krill-oil products had higher anisidine than plant-based products [1], and Hands et al. found fish/krill/calamari/mussel products had higher TOTOX than algae products (mean 42.7 vs. 12.9) [4]. The UAE study's lower overall TOTOX (mean 23.8) is likely explained in part by its smaller sample (44 products) and the fact that all products were collected from retail outlets and analyzed immediately, limiting exposure to ongoing deterioration [2, 2].

The market-survey data are not contradictory but are sampling different windows of the same deterioration trajectory: products fresh at retail but already oxidized from supply-chain exposure (Heller et al., Jairoun et al.) versus products assessed closer to their expiration date with accumulated in-package oxidation (Halvorsen & Blomhoff, Jackowski et al.). The weight of cross-study evidence supports the conclusion that a substantial minority of commercial omega-3 softgels—approximately 27–50% depending on product type, flavoring, and methodology—exceed at least one GOED voluntary oxidation limit at the point of testing, driven primarily by supply-chain and retail-storage inadequacies rather than by manufacturing quality failures at point of production.

Reconciling Shell-Material Effects on Oxidation Versus Bioavailability

The finding from Alberdi-Cedeño et al. that gelatin shells reduce digestion-induced oxylipin formation relative to starch shells [10] appears to conflict with the finding from Otálora et al. that gelatin/cactus-mucilage shells provide low protection of encapsulated PUFAs under gastric conditions, leading to low PUFA bioaccessibility [21]. The divergence is explained by context: Alberdi-Cedeño et al. compare two types of commercial softgel shell (starch vs. gelatin), showing gelatin generates less oxidation relative to starch, not that gelatin is an absolute barrier [10]. Otálora et al. assess an experimental Tier 2 gelatin/cactus-mucilage composite shell at an unusually low mucilage ratio, finding poor protection attributable to rapid gastric proteolysis of the gelatin component and the insufficient contribution of the poorly hydrolysis-resistant mucilage [21]. These studies are not contradicting each other but rather addressing different experimental contexts: relative oxidation performance between two commercial shell types (Alberdi-Cedeño et al.) versus absolute protective performance of an experimental low-mucilage composite shell (Otálora et al.). The evidence base does not support the conclusion that gelatin shells universally protect PUFAs during gastric digestion, but it does support the conclusion that gelatin is superior to starch as a shell material specifically for minimizing digestion-induced oxylipin formation.

The Dissolution–Crosslinking–Packaging Triangle

Three distinct failure modes affecting softgel dissolution—gelatin crosslinking, moisture ingress, and solubilization limitation—are mechanistically related but operate through different pathways that require distinct interventions. Bachour et al. establish that gelatin crosslinking sufficient to prevent rupture can develop during 18 months at conditions as mild as 25 °C/65% RH [8], yet commercial capsules at the time of manufacture pass the rupture test without difficulty [8]. Xu et al. demonstrate that soybean oil as the fill solvent limits water transfer from the gelatin shell, reducing the crosslinking risk and maintaining rapid dissolution [7, 7]. Visa et al. show that a superior moisture-barrier blister extends shelf life by approximately doubling the effective stability period at 25–30 °C, but cannot prevent drug–excipient reactions that generate impurities independently of moisture [9, 9]. Allam et al. demonstrate that vehicle polarity determines whether phase separation and solubilization collapse occur during storage—a failure mode distinct from crosslinking or moisture ingress [6, 6]. This triangular failure landscape implies that formulation teams must simultaneously address: (1) fill composition to minimize water activity at the shell–fill interface and prevent phase separation; (2) packaging barrier to control moisture and oxygen ingress; and (3) excipient compatibility to prevent chemical degradation pathways unrelated to either crosslinking or oxidation.